Table 2.

Novel target in myeloma, agents and stage of ongoing clinical trials

Cell surface targets
Target	Agent	Clinical Study Phase	Single Agent(S)/Combination(C)
FGF3	Dasatinib	I/II	S
FGF, PDGF	(mAb)TKI258	I	S
CD38	mAb	I	S
CD40	SGN-40 (mAb)	I/II	S, C (Lenalidomide)
	HCD122 (mAb)	I	S
CD56	huN901-DM1 (C-mAb)	I	S
CS1	HuLuc63 (mAb)	II/III	S, C (Lenalidomide, bortezomib)
CD138	BT062 (mAb-DM4)	I	S
RANKL	AMG162 (mAb)	I/II	S
MUC1	AR20.5 (mAb)	I/II	S
BAFFR	LY2127399 (mAb)	I/II	S
CD52	Alemtuzumab (mAb)	II	S
TRAIL	Apo2L/TRAIL (Apo2 ligand)	I	S
	Mapatumumab	I/II	S
IGF1/R	IGF1R CP-571 (mAb)	I	S
	EM164 (mAb)	I	S
IL6/R	CNTO328 (mAb)	II/III	S, C (bortezomib)
	Altizumab (mAb)	III	S
VEGF/R	Bevacizumab (mAb)	II	S
	SU5416	II	S
	Zactima (ZD6474)	II	S
DKK-1	BHQ-880	I/II	S
Activin A		I/II	S
KIR	IPH101	I/II	S
CXCR3	AMD3100	II	C (bortezomib)
Intracytoplasmic and/or nuclear targets
CDK	Alvocidib (NSC649890)	I	S
CDK and GSK3β	AT7519M	I/II	S, C (bortezomib)
IKK	RTA402	I	S
Akt	perofosine	III	C (bortezomib)
HDAC	panabinostat	III	C (bortezomib)
	Vorinostat	II/III	C (bortezomib)
	Romidopsin	II/III	C ( bortezomib)
Farnesyltransferase	Tipifarnib (R115777)	II	S, C (bortezomib)
HSP90	KOS953	II	C ( bortezomib)
	AUY922	II	C (bortezomib)
	IPI504	I/II	C (bortezomib)
Proteasome	Carfilzomib	II/III	S, C (lenalidomide)
	NPI-0052	I	S
	MLN9708	I	S
Mitochondria	GCS-100	I/II	C
mTOR	CCI-779 II	II	C (bortezomib)
	RAD001	II	C (lenalidomide, bortezomib)
	INK128	II	S
PKC	Enzastaurin	I/II	S, C (bortezomib)
Telomerease	GRN163L	I/II	S, C (bortezomib)

Data collected from National Cancer Institute Clinical Trials website, Multiple

Myeloma Research Foundation website and the International Myeloma Foundation website. mAb, monoclonal antibody.